Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) Equity Ratio (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Equity Ratio for 7 consecutive years, with 0.47 as the latest value for Q3 2024.

  • On a quarterly basis, Equity Ratio fell 5.04% to 0.47 in Q3 2024 year-over-year; TTM through Sep 2024 was 0.47, a 5.04% decrease, with the full-year FY2023 number at 0.45, down 23.28% from a year prior.
  • Equity Ratio was 0.47 for Q3 2024 at Actinium Pharmaceuticals, down from 0.49 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.95 in Q2 2021 to a low of 0.45 in Q4 2023.
  • A 4-year average of 0.67 and a median of 0.58 in 2022 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: fell 1.99% in 2022, then tumbled 39.26% in 2023.
  • Actinium Pharmaceuticals' Equity Ratio stood at 0.91 in 2021, then plummeted by 36.36% to 0.58 in 2022, then dropped by 23.28% to 0.45 in 2023, then rose by 4.17% to 0.47 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Equity Ratio are 0.47 (Q3 2024), 0.49 (Q2 2024), and 0.5 (Q1 2024).